MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug attack on rare blood cancer aims to free patients from transfusions
Disease control Recruiting nowThis study is testing whether combining two drugs, momelotinib and luspatercept, can help people with a rare bone marrow cancer called myelofibrosis who need frequent blood transfusions. The main goal is to see if the treatment can reduce or eliminate the need for transfusions ov…
Matched conditions: MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…
Matched conditions: MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC